<DOC>
	<DOCNO>NCT01925911</DOCNO>
	<brief_summary>To evaluate effect IPI-145 pharmacokinetics midazolam , cytochrome P450 3A ( CYP3A ) substrate ; ass safety tolerability IPI-145 administer midazolam healthy subject .</brief_summary>
	<brief_title>Phase 1 Study Healthy Subjects Evaluate Effect IPI-145 Pharmacokinetics Midazolam</brief_title>
	<detailed_description>- In Treatment Period 1 , subject receive single 2 mg oral dose midazolam . - In Treatment Period 2 , Days 2-6 , subject receive twice daily ( BID ) oral dose 25 mg IPI-145 ; Day 6 , subject receive morning dose 25 mg IPI-145 concomitantly administer 2 mg midazolam .</detailed_description>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy men woman nonchildbearing potential 1850 year age Body Mass Index ( BMI ) : 18.0 32.0 kg/m2 . In good health , determine clinically significant finding clinical evaluation Provided write informed consent prior study specific procedure Women childbearing potential Evidence clinically significant medical condition History gastrointestinal disease surgery may affect drug absorption Positive indeterminate tuberculosisspot test screen Any active infection time screen admission Subjects acute narrowangle glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>DDI</keyword>
	<keyword>CYP3A</keyword>
</DOC>